Specialized Resource A - Cyclotron Radiochemistry and Chemistry (SR-A). lCMlC-3 is reliant on the production and supply of existing and novel radiopharmaceuticals and radiochemicals. In this Specialized Resource we will continue to generate a tool box of radiolabeled drugs based around 18F-tracers as well as drugs based on the longer-lived nuclides 64Cu, 86Y, 89Zr and 124I. This will allow us to augment the existing lCMIC-3 projects, the ICMIC Developmental Projects, ultimately resulting in the ability to get a better understanding of the biology of cancer and to perform personalized medicine in our patients.
The Specific Aims of this Specialized Resource are as follows: (A) to undertake specialized radiochemistry and labeling chemistry in support of the ICMIC projects and developmental projects;(B) To function as an evolving resource - to provide (and design) new compounds as required as the ICMIC research matures; and, (C) to act as a central resource for the translation of new drugs to the clinical setting.
The Aims will be achieved by providing state-of-the-art radiochemistry facilities (including a $25M expansion over the next 5 years) to the ICMIC projects and developmental projects with high grade, GMP prepared (if required) radiotracers. This Specialized Resource will also be developmental in nature;as new chemicals and radiochemicals are required by the Projects, this Specialized Resource will respond by producing novel compounds as requested.

Public Health Relevance

This Specialized Resource will provide services and expertise in chemistry and radiochemistry to all four of the Research Projects within this ICMIC. This Specialized Resource we will generate a tool box of radiolabeled drugs that will allow us to augment the existing ICMIC projects, the ICMIC developmental projects and the new ICMIC research programs, ultimately resulting in the ability to get a better understanding of the biology of cancer and to perform personalized medicine in our patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Rodina, Anna; Wang, Tai; Yan, Pengrong et al. (2016) The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature 538:397-401
Lee, Sang-Gyu; Gangangari, Kishore; Kalidindi, Teja Muralidhar et al. (2016) Copper-64 labeled liposomes for imaging bone marrow. Nucl Med Biol 43:781-787
Demoin, Dustin Wayne; Shindo, Masahiro; Zhang, Hanwen et al. (2016) Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas. Nucl Med Biol 43:606-11
Arevalo-Perez, Julio; Paris, Manuel; Graham, Michael M et al. (2016) A Perspective of the Future of Nuclear Medicine Training and Certification. Semin Nucl Med 46:88-96
Cheal, Sarah M; Xu, Hong; Guo, Hong-Fen et al. (2016) Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging 43:925-37
Wang, Xiuyan; Rivière, Isabelle (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 3:16015
Cherkassky, Leonid; Morello, Aurore; Villena-Vargas, Jonathan et al. (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126:3130-44
Kadota, Kyuichi; Sima, Camelia S; Arcila, Maria E et al. (2016) KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. Am J Surg Pathol 40:1579-1590
Mayor, Marissa; Yang, Neng; Sterman, Daniel et al. (2016) Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 49:1324-33
Adusumilli, Prasad S (2016) Spread through alveolar spaces: An aerogenous invasion in pulmonary adenocarcinomas. J Thorac Cardiovasc Surg 152:73-4

Showing the most recent 10 out of 177 publications